Estate Counselors LLC Makes New $4.24 Million Investment in Elanco Animal Health Incorporated $ELAN

Estate Counselors LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 210,633 shares of the company’s stock, valued at approximately $4,242,000.

Other hedge funds also recently modified their holdings of the company. Hsbc Holdings PLC lifted its position in Elanco Animal Health by 434.2% during the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock worth $1,801,000 after acquiring an additional 102,686 shares during the last quarter. Norges Bank bought a new position in shares of Elanco Animal Health during the second quarter worth approximately $12,502,000. Amalgamated Bank lifted its holdings in Elanco Animal Health by 793.7% during the 3rd quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock worth $4,563,000 after purchasing an additional 201,226 shares during the last quarter. Yousif Capital Management LLC boosted its stake in Elanco Animal Health by 1,333.7% in the 3rd quarter. Yousif Capital Management LLC now owns 168,133 shares of the company’s stock valued at $3,386,000 after purchasing an additional 156,406 shares during the period. Finally, Equitable Trust Co. grew its holdings in Elanco Animal Health by 65.5% in the 2nd quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock valued at $3,543,000 after buying an additional 98,172 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ELAN shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, November 19th. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Finally, Barclays assumed coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.11.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $24.41 on Monday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The company has a market cap of $12.13 billion, a PE ratio of 406.90, a price-to-earnings-growth ratio of 3.39 and a beta of 1.87. The company has a 50 day moving average of $22.74 and a 200-day moving average of $20.05. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $25.29.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the business earned $0.13 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 22,000 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. This represents a 15.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Rajeev A. Modi bought 4,500 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the transaction, the insider owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 43,450 shares of company stock valued at $937,883 in the last quarter. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.